CAPR FY2025 EPS Estimate Boosted by Cantor Fitzgerald

Capricor Therapeutics, Inc. (NASDAQ:CAPR) – Research analysts at Cantor Fitzgerald raised their FY2025 earnings per share estimates for Capricor Therapeutics in a research report issued on Tuesday, November 11th. Cantor Fitzgerald analyst K. Kluska now anticipates that the biotechnology company will post earnings of ($2.22) per share for the year, up from their previous estimate of ($2.33). The consensus estimate for Capricor Therapeutics’ current full-year earnings is ($1.21) per share. Cantor Fitzgerald also issued estimates for Capricor Therapeutics’ FY2026 earnings at $0.96 EPS.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings data on Monday, November 10th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.54).

Several other research analysts have also issued reports on CAPR. Roth Capital raised their target price on Capricor Therapeutics from $12.00 to $13.00 and gave the stock a “buy” rating in a research report on Tuesday. HC Wainwright reissued a “buy” rating and set a $24.00 target price on shares of Capricor Therapeutics in a research report on Thursday, September 25th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Capricor Therapeutics in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $22.38.

Capricor Therapeutics Stock Down 1.4%

Shares of CAPR stock traded down $0.09 during trading hours on Thursday, hitting $5.79. 258,069 shares of the company’s stock traded hands, compared to its average volume of 1,833,748. The stock has a market cap of $264.47 million, a PE ratio of -3.53 and a beta of 0.58. The stock’s 50 day simple moving average is $6.55 and its 200 day simple moving average is $8.26. Capricor Therapeutics has a 12 month low of $5.43 and a 12 month high of $20.75.

Institutional Trading of Capricor Therapeutics

Institutional investors have recently bought and sold shares of the company. Bank of New York Mellon Corp boosted its holdings in shares of Capricor Therapeutics by 4.4% during the 1st quarter. Bank of New York Mellon Corp now owns 87,720 shares of the biotechnology company’s stock valued at $832,000 after acquiring an additional 3,693 shares during the last quarter. Arizona State Retirement System purchased a new position in shares of Capricor Therapeutics in the first quarter valued at about $111,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Capricor Therapeutics by 31.4% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,246 shares of the biotechnology company’s stock valued at $126,000 after buying an additional 3,162 shares during the last quarter. XTX Topco Ltd bought a new position in Capricor Therapeutics during the first quarter valued at approximately $521,000. Finally, Citizens Financial Group Inc. RI purchased a new position in Capricor Therapeutics in the first quarter worth about $95,000. 21.68% of the stock is owned by hedge funds and other institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.